Heart Failure start-up, Acorai, closes oversubscribed $4m funding round

Acorai AB Sweden France United Kingdom England Germany United States of America California

to get in touch or set up a meeting. 

About Acorai

Acorai is developing a non-invasive intracardiac pressure monitoring device to improve heart failure management for more than 64 million patients worldwide. Acorai's Monitoring system was designated a breakthrough device by the FDA in 2023 and is built upon the patented SAVE Sensor System, a proprietary, non-invasive hardware & machine learning platform.

Acorai is backed by Solardis Health Ventures, KHP Ventures, GA Investors, , and Life Science Invest with a seasoned medical device team and corporate advisory board with experiences from GE Healthcare, Verily & Abbott, and has established clinical partnerships with world-leading hospitals.

Visit https://acorai.com/ to learn more about Acorai's potential to become the new standard in heart failure management and a leader in non-invasive patient care.

Logo - https://mma.prnewswire.com/media/2183401/4224716/Acorai_AB_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/heart-failure-start-up-acorai-closes-oversubscribed-4m-funding-round-302037617.html

@ prnewswire.co.uk